Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate
Cardiac hypertrophy occurs in up to 95% of patients with CKD and increases their risk for
cardiovascular death. In the kidney, full-length membranous Klotho forms the coreceptor for
fibroblast growth factor 23 (FGF23) to regulate phosphate metabolism. The prevailing view is
that the decreased level of Klotho in CKD causes cardiomyopathy through increases in
serum FGF23 and/or phosphate levels. However, we reported recently that soluble Klotho
protects against cardiac hypertrophy by inhibiting abnormal calcium signaling in the heart …
cardiovascular death. In the kidney, full-length membranous Klotho forms the coreceptor for
fibroblast growth factor 23 (FGF23) to regulate phosphate metabolism. The prevailing view is
that the decreased level of Klotho in CKD causes cardiomyopathy through increases in
serum FGF23 and/or phosphate levels. However, we reported recently that soluble Klotho
protects against cardiac hypertrophy by inhibiting abnormal calcium signaling in the heart …